- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- YJ001 for Spray Use, Placebo of YJ001 for Spray Use
- Drug
- Lead sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fredericksburg, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 11,176
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small Cell Lung Cancer and Pleural Mesothelioma
- Interventions
- PTK787 and Pemetrexed with or without Cisplatin
- Drug
- Lead sponsor
- Nevada Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Primary Membranous Nephropathy
- Interventions
- budoprutug
- Drug
- Lead sponsor
- Climb Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 3 more
- Conditions
- Neoplasms
- Interventions
- VIP236 (Q3W), VIP236 (Q2W)
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- N-Power Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Monterey, California • Torrance, California • Walnut Creek, California + 7 more
- Conditions
- Solid Tumor, Leiomyosarcoma, Osteosarcoma
- Interventions
- M6620
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
- Interventions
- Cohort study
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Interventions
- Surzebiclimab, Tislelizumab, Alcestobart
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Acute Myocardial Infarction
- Interventions
- ClearWay™ Rx catheter
- Device
- Lead sponsor
- Cardiovascular Institute of the South Clinical Research Corporation
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Lafayette, Louisiana
- Conditions
- Juvenile and Adolescent Idiopathic Scoliosis
- Interventions
- differential rod bending with rod contours (MESA Spinal System)
- Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
- Interventions
- Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
- Behavioral · Drug
- Lead sponsor
- Noom Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Healthy Male
- Interventions
- GCC-4401, GCC-4401C
- Drug
- Lead sponsor
- Green Cross Corporation
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Osteoarthritis, Chronic Pain
- Interventions
- Phenotype assessment
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- NF1, Neurofibromatosis, Plexiform Neurofibromas
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Psoriasis (PsO)
- Interventions
- Deucravacitinib, Other systemic treatments for PsO
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Recurrent Pericarditis
- Interventions
- VTX2735
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • Orange, California • Saint Augustine, Florida + 10 more
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
- Interventions
- JANX007, Darolutamide
- Biological · Drug
- Lead sponsor
- Janux Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Interventions
- Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B, Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B, Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B, Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B, Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A
- Other
- Lead sponsor
- British American Tobacco (Investments) Limited
- Industry
- Eligibility
- 26 Years to 55 Years
- Enrollment
- 806 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 18
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 14 more
- Conditions
- Chronic Pain, Ketamine
- Interventions
- Ketamine (Ketalar)
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ovarian Cancer, Cancer of the Ovary, Ovarian Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 15,498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Interventions
- Bomedemstat, Venetoclax
- Drug
- Lead sponsor
- Terrence J Bradley, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Partial Oncolysis, SV-102
- Procedure · Drug
- Lead sponsor
- Syncromune, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 19 more